Table 1 Beta-emitting radionuclides applied in treating diseases
From: A machine learning-based model for a dose point kernel calculation
Radionuclide | Half-life [days] | \(E_{\rm avg}\)(\(E_{\rm max}\))[keV] | Therapeutic indication |
|---|---|---|---|
\(^{89}\)Sr | 50.6 | 587.1 (1502.2) | Relief of pain skeletal metastases |
\(^{90}\)Y | 2.7 | 932.4 (2275.6) | Hepatocellular cancer and liver metastasis Non-Hodgkin’s lymphoma |
\(^{131}\)I | 8.0 | 191.6 (806.9) | Hyperthyroidism, differentiated thyroid cancer Non-Hodgkin’s lymphoma |
\(^{177}\)Lu | 6.7 | 148.8 (496.8) | Neuroendocrine tumors Prostate tumors |
\(^{186}\)Re | 3.7 | 359.2 (1072.7) | Relief of pain, skeletal metastases |
\(^{188}\)Re | 16.7 | 795.4 (2120.4) | Relief of pain, skeletal metastases |